Clinical calculator summary
2025 ATA Estimated Risk of Structural Recurrence
Clinical calculator summary
2025 ATA Estimated Risk of Structural Recurrence
Initial postoperative adult DTC structural-recurrence category from ATA 2025 Figure 2.
Evidence-based context for fast calculator use
- Purpose:
- Source-specific category interpretation; not treatment selection or dynamic response assessment.
- Population:
- Adults with differentiated thyroid cancer after surgery and complete reconciled pathology/staging context.
- Factors:
- Tumor size/invasion, Histology/focality, Margins, Clinical and pathologic nodes, Extranodal extension, Distant metastasis, Vascular invasion
- Reference:
- Ringel MD, et al. 2025 ATA Guidelines. DOI 10.1177/10507256251363120.
2025 ATA Estimated Risk of Structural Recurrence for Adult Differentiated Thyroid Cancer
Clinical Context & Background
Strict ATA 2025 Figure 2 decision tree; raw measurements are not rounded and Low is never a fallback.Reference Data
| ATA 2025 category | Source estimate up to 10 years | Automated interpretation |
|---|---|---|
| Low | <10% | Only when all Low requirements are affirmatively established |
| Low-intermediate | 10-15% | One source-defined low-intermediate factor |
| Intermediate-high | 16-30% | Specific source branch or at least two low-intermediate factors |
| High | >30% | One source-defined high factor; may be determinative despite lower-order unknowns |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Initial postoperative adult differentiated thyroid cancer assessment, generally within about three months of surgery.
How To Interpret
- Read the source category and controlling factors; percentages are category labels, not a calculated individual probability.
What To Do Next
- Reconcile the result with the full pathology report, AJCC8 staging, postoperative imaging, Tg/TgAb context, and specialist judgment.
Limitations
- Not for pediatric, medullary, anaplastic, benign/NIFTP, preoperative, dynamic-response, recurrent-disease, or treatment selection use.
Validated Population
Adult postoperative PTC, FTC/IEFVPTC, and oncocytic thyroid carcinoma represented by the ATA 2025 framework.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through the visible production controls across Low, Low-intermediate, and High ATA 2025 categories.
- The exact just-above-4-cm transition and gross strap-muscle invasion branch matched the source decision tree.
- No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/ata-thyroid-cancer-risk-stratification-2026-08-03.json.
: Production browser validation
- All ten source-backed calculations and dispositions matched the ATA 2025 Figure 2 oracle across 11 visible Calculate attempts.
- The matrix covered all four categories, raw tumor and node thresholds, factor-count escalation, papillary and follicular conditional inputs, high-risk precedence, pediatric outside scope, and reset/repeat behavior.
- Calculator UI behavior passed without stale state or unexpected output; overall browser status was failed-console because production emitted React hydration error #418.
Case-level production evidence is retained in validation/browser-production/ata-thyroid-cancer-risk-stratification.json.
: Input workflow simplified and revalidated
- Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
- Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
- Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.
: Model source lock corrected
- Retired the simplified 2015 checklist behavior and locked the permanent route to ATA 2025 Figure 2.
- Separated initial structural-recurrence estimation from treatment decisions and dynamic response assessment.
: Calculation and input contract corrected
- Implemented the strict 24-key raw contract, exact size/node/vessel equalities, precedence, factor counting, and no-Low-fallback rule.
- Removed defaults, coercion, pre-binned features, TSH/RAI directives, and unsupported recurrence outputs.
: Full implementation validation completed
- Passed 2,640 deterministic assertions using an independently encoded literal oracle.
- Verified workbook, evidence mirrors, source trace, immutable inputs, registry, generated assets, and linked-content parity.
Implementation verification only; not prospective clinical validation.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should 2025 ATA Estimated Risk of Structural Recurrence for Adult Differentiated Thyroid Cancer be used?
Use it for patients with differentiated thyroid cancer pathology in the staging or recurrence-risk setting described by the model when all required inputs and the intended clinical setting are confirmed.
Can 2025 ATA Estimated Risk of Structural Recurrence for Adult Differentiated Thyroid Cancer determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.